4D Molecular Therapeutics, Inc. (FDMT)
10.80
-1.05
(-8.86%)
USD |
NASDAQ |
Oct 23, 16:00
10.78
-0.02
(-0.23%)
After-Hours: 20:00
4D Molecular Therapeutics Gross Profit Margin (Quarterly) : 44.75% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 44.75% |
| March 31, 2026 | 32.56% |
| December 31, 2025 | 97.67% |
| September 30, 2025 | -2.13K% |
| June 30, 2025 | -12.49K% |
| March 31, 2025 | -12.43K% |
| December 31, 2024 | -178.3K% |
| September 30, 2024 | -56.67K% |
| June 30, 2024 | -32.38K% |
| March 31, 2024 | -5.59K% |
| September 30, 2023 | 93.09% |
| June 30, 2023 | -497.5% |
| March 31, 2023 | -373.8% |
| Date | Value |
|---|---|
| December 31, 2022 | -11.31% |
| September 30, 2022 | -75.80% |
| June 30, 2022 | -413.0% |
| March 31, 2022 | 35.85% |
| December 31, 2021 | -1.95K% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| Anika Therapeutics, Inc. | 65.15% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
| Imunon, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -41.57% |
| Return on Assets | -36.27% |
| Return on Invested Capital | -39.27% |
| Profit Margin (Quarterly) | -1.93K% |
| Operating Margin (Quarterly) | -2.04K% |
| Return on Net Operating Assets | -542.6% |